PfSPZ Malaria Vaccine

Novitasari, Dwi Ayu Fani (2022) PfSPZ Malaria Vaccine. International Journal of Science and Research (IJSR), 11 (3). pp. 76-77. ISSN 2319-7064

[thumbnail of Dwi Ayu Fani_PfSPZ Malaria Vaccine.pdf] PDF
Dwi Ayu Fani_PfSPZ Malaria Vaccine.pdf

Download (124kB)
Official URL / DOI:


Malaria is a disease caused by parasites. As we know that parasites have 3 life cycles while it’s on the human host: pre-erythrocytes phase, blood-stage phase, and transmissionblocking phase. As for now, the medicine for malaria disease is artemisin combination therapy which is going to be resistant, so people try to develop a vaccine for malaria to meet the goal of malaria eradication. One of the vaccines developed is RTS,S/AS01. RTS,S/AS01 is pre-erythrocytic vaccine that confers efficacy against controlled human malaria infection in about 22% in healthy malaria 5 months after vaccination. In clinical trial phase 3, RTS,S/AS01 was 26% in young infants and 36% in children (Ishizuka et al., 2016). Eradication of malaria needs vaccine protection of more than 80% and has protective efficacy for more than 6 months. Therefore, the development of a malaria vaccine is still needed. Another malaria vaccine is PfSPZ. PfSPZ is pre-erythrocytic stage vaccine similar to RTS,S/AS01. It is whole attenuated sporozoite Plasmodium falciparum.

Item Type: Article
Uncontrolled Keywords: vaccine, malaria, PfSPZ
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Pharmacy > Department of Pharmacy
Depositing User: Dwi Ayu Fani Novitasari
Date Deposited: 21 Mar 2022 02:06
Last Modified: 29 Mar 2022 03:04

Actions (login required)

View Item View Item